-
Zanidatamab Plus Chemotherapy Shows Promising Anti-Tumor Activity in Treatment of HER2-Mutated Breast Cancer
21 May 2025 23:08 GMT
… (HER2)-mutated metastatic breast cancer (mBC). The data … for Medical Oncology Breast Cancer 2025 Annual Meeting … Bristol Myers Squibb], capecitabine [Xeloda; Genetech, Roche], or vinorelbine … with HER2-mutated metastatic breast cancer, particularly those who …
-
T-DXd Improves All Outcomes in Post-Hoc Look of DESTINY-Breast06 in HR+, HER2-Low/-Ultralow Metastatic Breast Cancer
15 May 2025 21:24 GMT
… physician’s choice with capecitabine (Xeloda) or taxane (nab-paclitaxel [ … low or HER2-ultralow metastatic breast cancer, according to additional data from … identify patients with HER2-ultralow breast cancer.
Additional Trial Objectives, Findings, and …
-
Pyrotinib-Based Therapy May Improve Survival in Patients With HER2+ Breast Cancer and Liver Metastases
25 Apr 2025 15:47 GMT
… (HER2+) advanced metastatic breast cancer (mBC) with liver … in combination with capecitabine (Xeloda; Genentech) for advanced … positive liver metastatic advanced breast cancer. Front Oncol. April … for HER2-positive metastatic breast cancer: a systematic review …
-
FDA Approves T-DXd in HR+, HER2-Low/Ultralow Breast Cancer
28 Jan 2025 00:55 GMT
… without targeted therapy for metastatic breast cancer. Alternatively, they could have … chemotherapy, which consisted of capecitabine (Xeloda; 59.8%), nab-paclitaxel (Abraxane … low or HER2-ultralow metastatic breast cancer following disease progression after …
-
Low ctDNA Levels May Show Longer Recurrence-Free Interval in Breast Cancer
20 Dec 2024 23:12 GMT
… patients with triple-negative breast cancer (TNBC), circulating tumor … subset having HR–positive breast cancer (12 patients).
Among … .8%) and prior therapy Xeloda, (capecitabine) 13.5%). … triple-negative breast cancer or HER2-, BRCA-mutated breast cancer with …
-
The Evolution of ADCs in Breast Cancer: Challenges and Innovations
12 Dec 2024 08:02 GMT
… breast cancer (BC). At the 2024 San Antonio Breast Cancer … ; Novartis) plus capecitabine (Xeloda; Genentech) (9.6 … advanced or metastatic breast cancer (EMILIA). ClinicalTrials.gov … (HER3) positive metastatic breast cancer. ClinicalTrials.gov Identifier: …
-
T-DXd Improves PFS Irrespective of Time to Progression, Type of Endocrine Resistance in HER2-Low/-Ultralow Metastatic Breast Cancer
11 Dec 2024 19:52 GMT
… hormone receptor–positive metastatic breast cancer with HER2-low ( … which consisted of capecitabine (Xeloda; 59.8%), nab-paclitaxel … Presented at: San Antonio Breast Cancer Conference; December 10-13 … or HER2-ultralow metastatic breast cancer (mBC) with prior …
-
Side Effects, Quality of Life Important to Consider in Breast Cancer Subset
29 Sep 2024 17:51 GMT
… -nxki) for HER2-positive metastatic breast cancer showed “remarkable” outcomes, although it … the regimen of [Tukysa] (tucatinib), [Xeloda] (capecitabine) and Herceptin (trastuzumab). That … With the [Herceptin, Tukysa and Xeloda] regimen, we see more diarrhea …
-
Dato-DXd Did Not Achieve Statistically Significant OS in Patients With Breast Cancer
24 Sep 2024 18:59 GMT
… cancer, triple-negative breast cancer, and HR+/HER2- breast cancer. Specifically, 7 … consisted of either oral capecitabine (Xeloda; Genentech), IV gemcitabine (Gemzar; … care for patients with metastatic breast cancer with [trastuzumab deruxtecan (Enhertu; …
-
Tucatinib Retains its Role in HER2+ Metastatic Breast Cancer, Prompting Questions of T-DXd’s Potential Takeover in the First Line
24 Jul 2024 15:46 GMT
… trastuzumab (Herceptin) and capecitabine (Xeloda) vs fam-trastuzumab deruxtecan-nxki … with metastatic HER2-positive breast cancer and central nervous system … pertuzumab in HER2-positive metastatic breast cancer (DESTINY-Breast09). ClinicalTrials.gov. …
About
© 1995-2025